Key statistics dashboard for Adaptimmune Therapeutics plc (ADAP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
Stock Data
| Price | $0.05 |
| Market Cap | $75M |
| Enterprise Value | $97.8M |
| Beta | 2.49 |
| Exchange | NASDAQ |
| Country | GB |
Valuation Multiples
| P/E Ratio | -0.16 |
| Price / Book | -0.18 |
| P/S | 3.59 |
| EV/EBITDA | -1.42 |
| EV/Sales | 4.66 |
| EV/FCF | -0.95 |
| P/FCF | -0.73 |
| Earnings Yield | -608.39% |
| FCF Yield | -136.58% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 83.88% |
| EBIT Margin | -352.51% |
| EBITDA Margin | -328.78% |
| Operating Margin | -362.66% |
| Net Margin | -371.74% |
| Return on Equity | 143.79% |
| Return on Assets | -59.65% |
| Return on Invested Capital | -90.90% |
| Return on Capital Employed | -96.08% |
Financial Health
| Current Ratio | 1.52 |
| Quick Ratio | 1.29 |
| Cash Ratio | 0.51 |
| Debt / Equity | -0.69 |
| Debt / Assets | 37.26% |
| Net Debt / EBITDA | -0.33 |
| Interest Coverage | -26.74 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -5.47 |
Per-Share Data
| Revenue per share | 0.08 |
| Book Value per share | -0.27 |
| Cash per share | 0.10 |
| FCF per share | -0.39 |
| Tangible Book Value per share | -0.28 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 4 |
| Sell | 3 |
| Strong Sell | 0 |
| Total analysts | 16 |
| Avg rating (1-5) | 0.38 |
Related companies: ANL · APLM · BLRX · ERNA · GOVX · LNAI · LPCN
Explore sector: Healthcare · Biotechnology
More sections of ADAP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks